Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice
Plant systems offer scalable and cost-effective platforms for antibody production, but plant-specific glycans may affect pharmacokinetics and immunogenicity. To evaluate the impact of Fc glycosylation, four Pembrolizumab glycovariants were generated in Nicotiana benthamiana: wild-type glycosylation...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2025-12-01
|
| シリーズ: | Biotechnology Reports |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2215017X25000542 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|